The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 15, 2020
Filed:
Jul. 30, 2017
Applicant:
Kowa Company, Ltd., Aichi, JP;
Inventors:
Ryu Oshima, Tokyo, JP;
Gary Gordon, Morrisville, NC (US);
Assignee:
Kowa Company, Ltd., Aichi, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/423 (2006.01); A61K 31/366 (2006.01); A61K 31/40 (2006.01); A61K 31/47 (2006.01); A61K 31/505 (2006.01); A61K 31/41 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/423 (2013.01); A61K 9/0053 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/41 (2013.01); A61K 31/47 (2013.01); A61K 31/505 (2013.01); A61K 45/06 (2013.01);
Abstract
The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.